Drug
[18F]THK-5351
[18F]THK-5351 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 66.7%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
1
20%
Ph phase_2
4
80%
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(2)
Other(1)
Detailed Status
Completed2
Terminated1
unknown1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 24 (80.0%)
Trials by Status
terminated120%
completed240%
unknown120%
withdrawn120%
Recent Activity
0 active trials
Showing 5 of 5
unknownphase_2
The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome
NCT04572477
completedphase_2
[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
NCT02656498
completedphase_1
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
NCT03112096
terminatedphase_2
Imaging Tau in Alzheimer's Disease and Normal Aging
NCT02884492
withdrawnphase_2
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
NCT03024944
Clinical Trials (5)
Showing 5 of 5 trials
NCT04572477Phase 2
The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome
NCT02656498Phase 2
[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
NCT03112096Phase 1
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
NCT02884492Phase 2
Imaging Tau in Alzheimer's Disease and Normal Aging
NCT03024944Phase 2
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5